Clin2
NCT07228702Worth exploringEnrolling by invitation

Bacteriophage therapy for one patient with lung infection

Non-Tuberculous Mycobacterial (NTM) PneumoniaMycobacterium Abscessus Infection

Treatments studied

Part of Infections, Lungs & breathing clinical trials.

This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
1 people
Ages
Any age
Study type
Interventional

Who can take part

  • You must be the specific patient being considered for this study.
  • You must give your consent to participate.
  • You must have a lung infection caused by Mycobacterium abscessus.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07429162Not yet recruiting· Phase 1
Phage therapy for hard-to-treat lung infection

This trial tests whether bacteriophages—viruses that kill bacteria—can help treat a chronic lung infection caused by a drug-resistant bacterium called Mycobacterium abscessus.

NCT07485010Not yet recruiting· Phase 2
A new antibiotic combo for mycobacterium abscessus lung infection

This trial tests a new combination of antibiotics (Arm D) against the standard treatment for people with a difficult-to-treat lung infection called Mycobacterium abscessus. It is for adults and teens aged 12 and older, including those with cystic fibrosis.

NCT07372781Enrolling by invitation· Phase 2
Contezolid for mycobacterium abscessus lung infection

This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.

Beijing, Beijing Municipality
NCT07615309Enrolling by invitation
Omadacycline for Mycobacterium abscessus lung infection

This trial tests whether omadacycline (an antibiotic) can safely and effectively treat a rare lung infection caused by Mycobacterium abscessus bacteria. If you have this infection, this study may help doctors understand if this antibiotic works better than current treatments.

Beijing
NCT06262282Enrolling by invitation
Phage therapy for stubborn NTM infection in cystic fibrosis

This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.

Birmingham, Alabama
NCT07076238Recruiting
Phage therapy for hard-to-treat bacterial infections

This study looks at how well phage therapy works for people with stubborn bacterial infections, like NTM. If your doctor is already considering phage therapy as part of your care, this trial may help track your response.

New York, New York

Hear when a new Mycobacterium Abscessus Infection trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.